Characteristics and outcomes of gallbladder cancer patients at the Tata Medical Center, Kolkata 2017–2019

Author:

Dutta Anindita12,Mungle Tushar3ORCID,Chowdhury Nandita1,Banerjee Pritha3,Gehani Anisha4,Sen Saugata4,Mallath Mohandas5,Roy Paromita6,Krishnan Shekhar237ORCID,Ganguly Sandip8,Banerjee Sudeep9,Roy Manas9,Saha Vaskar127ORCID

Affiliation:

1. Cell Biology Tata Translational Cancer Research Centre Kolkata India

2. Division of Cancer Sciences University of Manchester Manchester UK

3. Clinical Research Unit Tata Translational Cancer Research Centre Kolkata India

4. Department of Radiology Tata Medical Center Kolkata India

5. Department of Digestive Diseases Tata Medical Center Kolkata India

6. Department of Histopathology Tata Medical Center Kolkata India

7. Department of Paediatric Haematology and Oncology Tata Medical Center Kolkata India

8. Department of Medical Oncology Tata Medical Center Kolkata India

9. Department of Gastrointestinal and Hepatobiliary Surgery Tata Medical Center Kolkata India

Abstract

AbstractBackgroundThe north and north‐eastern regions of India have among the highest incidence of gallbladder cancer (GBC) in the world. We report the clinicopathological charateristics and outcome of GBC patients in India.MethodsElectronic medical records of patients diagnosed with GBC at Tata Medical Center, Kolkata between 2017 and 2019 were analyzed.ResultsThere were 698 cases of confirmed GBC with a median age of 58 (IQR: 50–65) years and female:male ratio of 1.96. At presentation, 91% (496/544) had stage III/IV disease and 30% (189/640) had incidental GBC. The 2‐year overall survival (OS) was 100% (95% CI: 100–100); 61% (95% CI: 45–83); 30% (95% CI: 21–43); and 9% (95% CI: 6–13) for stages I–IV, respectively (p = <0.0001).   For all patients, the 2‐year OS in patients who had a radical cholecystectomy followed by adjuvant therapy (N = 36) was 50% (95% CI: 39–64), compared to 29% (95% CI: 22–38) for those who had a simple cholecystectomy and/or chemotherapy (N = 265) and 9% (95% CI: 6–14) in patients who were palliated (N = 107) (p = <0.0001).ConclusionThe combined surgical/chemotherapy approach for patients with stage II GBC showed the best outcomes. Early detection of GBC remains problematic with the majority of patients presenting with stage III–IV and who have a median survival of 9.1 months. Our data suggests that the tumor is chemoresponsive and multi‐center collaborative clinical trials to identify alternative therapies are urgently required.

Funder

Union for International Cancer Control

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference40 articles.

1. Gallbladder cancer: epidemiology and outcome;Hundal R;Clin Epidemiol,2014

2. Epidemiology of digestive tract cancers in India IV. Gall bladder and pancreas;Dhir V;Indian J Gastroenterol,1999

3. Epidemiology and Molecular Pathology of Gallbladder Cancer

4. ICMR Three‐Year Report of the PBCRs: 2012–2014.2015.https://ncdirindia.org/ncrp/all_ncrp_reports/pbcr_report_2012_2014/all_content/pdf_printed_version/chapter8_printed.pdfAccessed September 1 2022.

5. Epidemiology of gallbladder cancer in India

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3